Home
Tubulis GmbH

Tubulis GmbH Market Share Analysis for March 2026

Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target

Industry: N/A

Domaintubulis.com

Year Founded2016

Employees51 - 200

Annual Revenue$75M - $100M

Tubulis GmbH

Tubulis GmbH (including company regionals)

tubulis.com

See more website traffic and engagement information

Tubulis GmbH Revenue up to March 2026 is 75M - 100M

revenue generated by Tubulis GmbH top domains

Tubulis GmbH top domains revenue over 3 years

Revenue for Tubulis GmbH top domains

tubulis.com75M - 100M

See more with Sales Intelligence

Total visits to Tubulis GmbH's top domains

Understand Tubulis GmbH market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

tubulis.com16.5K

See more with Sales Intelligence

Avg. visit duration in Tubulis GmbH's top domains

Analyze Tubulis GmbH engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

tubulis.com00:03:43

See more with Sales Intelligence

Avg. pageviews on Tubulis GmbH's top domains

See how Tubulis GmbH keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

tubulis.com2.34

See more with Sales Intelligence

Tubulis GmbH top competitors by domain

Top similar sites in March 2026, ranked by their affinity

gilead.comCompany NameGileadEmployees> 10001HQUnited States, California, Foster CityAnnual revenue> $1BTotal visits524.9KHealth > Health - Other

Top technologies used by Tubulis GmbH

These are the website technologies, by industry, used by Tubulis GmbH top domains

Payment & Currencies (10)

Cart Functionality

eCommerce (5)

WooCommerce

Widget (5)

Twemoji

Content Management System (4)

WordPress

More Technologies

9

See all

News & Signals from Tubulis GmbH

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTubulis GmbH is developing P5 technology.Tubulis has further developed P5 technology for clinical research and application in collaboration with the research group led by Prof. Dr. Heinrich Leonhardt (Ludwig Maximilian University of Munich), a co-founder of Tubulis.

NewsTubulis GmbH is developing TUB-030.Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications.

NewsTubulis GmbH is developing antibody-drug conjugate platform targeting solid tumors on Jul 1st '24.EQT Life Sciences co-led the oversubscribed Series B2 financing in 2024, and since then, has helped Tubulis advance into a clinical-stage oncology player, progress its pipeline, and build a differentiated antibody-drug conjugate platform targeting solid tumors.